Let me be blunt with you for just a second… You may think you know when and why stocks move, but you’re wrong… Most traders have no idea about the biggest secret Wall Street keeps — even though it’s hiding in plain sight. But once you’ve cracked this code… It could be the breakthrough you need to start targeting $100-$150 a day in the stock market (starting with just $1,000)!

Carl Gordon Biography and Net Worth

Director of ORIC Pharmaceuticals

Carl L. Gordon, PhD, CFA, is a founding Partner and Co-Head of Global Private Equity at OrbiMed. He was a senior biotechnology analyst at Mehta and Isaly from 1995 to 1997. He was a Fellow at The Rockefeller University from 1993 to 1995. For the last five years (2014 to 2018) Forbes^® Magazine named Mr. Gordon one of the top 100 venture capitalists in the world when it placed him on the “Forbes Midas List.” Dr. Gordon currently serves on the boards of directors of Turning Point Therapeutics and Prevail Therapeutics, as well as several private companies. Carl received a PhD in molecular biology from the Massachusetts Institute of Technology (1993) and a Bachelor of Arts Degree from Harvard College (1987).

What is Carl L. Gordon's net worth?: The estimated net worth of Carl L. Gordon is at least $1.02 million as of August 13th, 2024. Mr. Gordon owns 119,522 shares of ORIC Pharmaceuticals stock worth more than $1,015,937 as of November 15th. This net worth approximation does not reflect any other investments that Mr. Gordon may own. Learn More about Carl L. Gordon's net worth.
How do I contact Carl L. Gordon?: The corporate mailing address for Mr. Gordon and other ORIC Pharmaceuticals executives is 240 E. GRAND AVE. 2ND FLOOR, SOUTH SAN FRANCISCO CA, 94080. ORIC Pharmaceuticals can also be reached via phone at 650-388-5600 and via email at [email protected]. Learn More on Carl L. Gordon's contact information.
Has Carl L. Gordon been buying or selling shares of ORIC Pharmaceuticals?: Carl L. Gordon has not been actively trading shares of ORIC Pharmaceuticals in the last ninety days. Most recently, Carl L. Gordon sold 75,555 shares of the business's stock in a transaction on Monday, March 29th. The shares were sold at an average price of $23.31, for a transaction totalling $1,761,187.05. Learn More on Carl L. Gordon's trading history.
Who are ORIC Pharmaceuticals' active insiders?: ORIC Pharmaceuticals' insider roster includes Jacob Chacko (CEO), Carl Gordon (Director), Richard Heyman (Director), and Richard Scheller (Director). Learn More on ORIC Pharmaceuticals' active insiders.
Are insiders buying or selling shares of ORIC Pharmaceuticals?: During the last twelve months, insiders at the sold shares 3 times. They sold a total of 33,779 shares worth more than $339,287.96. The most recent insider tranaction occured on February, 6th when CEO Jacob Chacko sold 13,958 shares worth more than $169,170.96. Insiders at ORIC Pharmaceuticals own 5.6% of the company. Learn More about insider trades at ORIC Pharmaceuticals.
Information on this page was last updated on 2/6/2024.

Carl L. Gordon Insider Trading History at ORIC Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
3/29/2021	Sell	75,555	$23.31	$1,761,187.05
3/22/2021	Sell	7,673	$26.47	$203,104.31
3/19/2021	Sell	21,275	$26.47	$563,149.25

Carl L. Gordon Buying and Selling Activity at ORIC Pharmaceuticals

ORIC Pharmaceuticals Company Overview

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Today's Range

Now: $8.50

$8.10

$9.05

50 Day Range

MA: $9.72

$8.15

$11.25

2 Week Range

Now: $8.50

$6.33

$16.65

Volume

508,297 shs

Average Volume

518,164 shs

Market Capitalization

$599.82 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.13

Let’s be blunt

From DTI | Ad

Check out the $100 Challenge now